Web10 jun. 2012 · The pharmacokinetics and metabolic studies of mitomycin C demonstrate a rapid elimination pattern for the drug (alpha half-life of 8 min and beta, or terminal, half-life of 48 min), and an absolute requirement for reductive enzymatic activation of the drug to mono- and bifunctional alkylating species [3]. Web10 feb. 2024 · Mitomycin is not cell cycle specific but has its maximum effect against cells in late G and early S phases (Perry 2012). During use in trabeculectomy (filtration surgery) …
Mitomycin C - Wikipedia
Web21 jul. 2009 · Mitomycin (T3D2743) Identification Taxonomy Biological Properties Physical Properties Toxicity Profile Spectra Concentrations Links References Gene Regulation XML Targets (1) Targets 1. DNA General Function: Used for biological information storage. Specific Function: Webhalf-life – normal/ESRD (hrs) :50 minutes/– DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 20 to 50 : Dose as in normal renal function ; 10 to 20 : Dose as in normal renal function ; 10 : 75% of normal dose DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES ; CAPD :Unknown dialysability. Dose as in GFR 10 mL/min rajni sinha
Transient Mitomycin C-treatment of human corneal …
Webadministration of (14)C labeled HPBCD, a half-life in the plasma of 0.4 hours and 0.8 hours was found for rats and dogs respectively. A plasma clearance of 512 and 188 ml/kg/h was calculated for rats and dogs. The subchronic toxicity studies with rats, no adverse effects were found in rats treated intravenously with 50 mg/Kg HPBCD. At 100 mg/Kg ... Webwww.ncbi.nlm.nih.gov Web25 jul. 2024 · Mitomycin is a medication used in the treatment of anal carcinoma, bladder carcinoma, breast carcinoma, head and neck malignancies, and some other gastrointestinal carcinomas. It is in the antineoplastic antibiotic class of medications. This activity reviews the mechanism of action, adverse event profile, indication, and contraindication for ... rajni singh